* BIOLASE Inc BIOL.OQ BIOL.O is expected to show a rise
in
quarterly revenue when it reports results on May 11.
* The Foothill Ranch California-based company is expected
to
report a 0.1% increase in revenue to $10.178 million from
$10.17 million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. The company's guidance on
March 28 2023, for the period ended March 31, was for revenue of
$11.180 million.
* Refinitiv's mean analyst estimate for BIOLASE Inc is for
a loss
of 20 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for BIOLASE Inc
is
$1.75, above its last closing price of $0.20.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.64 -0.64 -1.28 Missed -101
Sep. 30 2022 -0.85 -0.84 -1.10 Missed -30.4
Jun. 30 2022 -0.64 -0.62 -0.91 Missed -46.2
Mar. 31 2022 -0.79 -0.68 -0.81 Missed -19.1
Dec. -0.62 -0.75 Missed -20
31 2021
Sep. 30 2021 -0.62 -0.69 -0.50 Beat 27.3
Jun. 30 2021 -1.13 -1.08 -0.50 Beat 53.8
Mar. 31 2021 -1.25 -1.25 -1.50 Missed -20
This summary was machine generated May 10 at 02:01 GMT. All
figures in US dollars unless otherwise stated